Faes Farma

Faes Farma is a 93-year-old Bilbao-headquartered specialty pharmaceutical company founded in 1933, still controlled by the founding families (Aristrain, Etxabe, Echevarria) with a combined ~30 percent stake. The company is a rare animal in European healthcare: profitable, dividend-paying, defensive (beta 0.34), with a single blockbuster molecule that generates royalty cash from 130+ countries — and a market capitalization of just 1.43 billion EUR.

The hero product is bilastine, a second-generation non-sedating H1 antihistamine sold under brand names Bilaxten (Spain), Ilaxten, Robilas, Lergonix and ~40 other regional names. Bilastine is approved in 130+ countries, sold by 30+ licensing partners (Menarini, Astellas, Faes itself in core markets), and generates approximately 35 to 40 percent of group EBITDA via a combination of direct sales and out-licensing royalties. The molecule was discovered in-house at Faes laboratories in the 1990s and the European composition-of-matter patent expired in 2022 — but extensive formulation patents (orodispersible tablet, pediatric oral solution) extend exclusivity in key markets through 2030 to 2034.

Beyond bilastine, Faes operates three other segments. Pharmaceutical specialties (own and licensed branded drugs in Spain, Portugal, Italy, Latin America) — Hidroferol (vitamin D for osteoporosis), Lertamine (loratadine), Provisacor (rosuvastatin generic), Ferplex (iron supplement). Animal nutrition and health (the segment is called Ingaso Farm) — premixes, additives and specialty feed for swine, poultry, cattle; the third-largest premix producer in Spain. Pharmaceutical raw materials — active pharmaceutical ingredients and intermediates sold to third-party drug manufacturers.

At 4.59 EUR, the stock trades at 18.4x trailing P/E, 13.1x forward P/E, EV/EBITDA roughly 9x, and offers a 3.92 percent dividend yield with a sustainable 51 percent payout ratio. The company has run net cash for the past decade and operates with a debt-to-equity of 58 percent (mostly long-dated infrastructure debt against owned manufacturing facilities). This is the kind of underfollowed Iberian healthcare compounder where the family-control alignment, the bilastine cash royalty engine, and the structural defensiveness combine into a quietly attractive risk-reward.

The Aristrain, Etxabe and Echevarria families collectively control approximately 30 percent of Faes Farma through a combination of direct holdings and family investment vehicles (Inveralava, Hempel, Eugur). This is third-generation family ownership — the original founders Aristrain and Etxabe started the company in 1933, and the current chairman Mariano Ucar Angulo is the son-in-law of one of the founding-family branches. The family control is not a passive arrangement: family representatives hold three of the eleven board seats and have actively blocked two informal takeover approaches from larger European pharma since 2015.

Institutional ownership is dominated by Spanish and pan-European specialist healthcare funds: Bestinver Asset Management (3.4 percent, value-oriented Spanish house), Magallanes Value Investors (2.8 percent), Cobas Asset Management (1.6 percent, Francisco Garcia Parames vehicle), Sycomore Asset Management (Paris, 1.4 percent). Notably absent from the top-ten holders: any US institutional name. Faes Farma trades approximately 350,000 shares per day on the Madrid stock exchange — too small for most US large-cap healthcare funds, too obscure for emerging-markets allocators.

Insider activity in 2025 was net-buying. Chairman Mariano Ucar purchased 75,000 shares at 3.85 EUR in March 2025 (a 290,000 EUR open-market buy at then-five-year-lows). CFO Iratxe Iribarne added 25,000 shares at 4.10 EUR in July 2025. Short interest is essentially zero (~0.3 percent of float) — there is no short thesis, but there is also no squeeze setup. The stock moves on Spanish small-cap newsflow and dividend-date timing, not on macro flow.

At 4.59 EUR Faes Farma trades at 18.4x trailing P/E, 13.1x forward P/E, EV/EBITDA roughly 9x, P/Sales 2.7x, P/Book 2.4x. The forward earnings yield is 7.6 percent and the free-cash-flow yield is 6.8 percent. The 3.92 percent dividend at 51 percent payout has 78 years of continuity. Sum-of-parts framework: bilastine royalty franchise valued at 6x recurring EBITDA = 700 to 750 million EUR; specialty pharma branded business at 8x EBITDA = 350 to 400 million EUR; Ingaso animal nutrition at 12x EBITDA = 480 to 580 million EUR; raw materials at 4x EBITDA = 50 million EUR; minus net debt of 80 million EUR; total = 1.5 to 1.7 billion EUR or 5.30 to 5.95 EUR per share — implying 15 to 30 percent upside. Spanish broker consensus targets are 4.95 EUR (Renta 4), 5.20 EUR (Bankinter), 5.50 EUR (BPI). The bear-case scenario of accelerated post-2030 bilastine generic erosion combined with a soft pork cycle could re-rate the stock to 3.50 to 3.80 EUR — roughly 20 percent downside. Risk-reward is approximately 1.5-to-1 favorable.

1. Q3 2026 results (October 2026):

   Bilastine licensing renewals with Menarini (Italy and France) expire in 2027 and management has indicated negotiations are ongoing. A multi-year renewal at improved royalty rates would lock in the cash engine through the 2030 to 2034 formulation patent expiry.

2. Capital Markets Day H1 2027:

   Management has not held a dedicated CMD since 2019. Activist push from value funds (Cobas, Magallanes) for a refreshed mid-term plan and explicit post-bilastine pipeline disclosure would be a re-rating catalyst.

3. Strategic combination scenario (any year):

   Speculative. Faes has been informally approached twice (per Spanish press) by larger European specialty pharma. The family-control structure makes hostile bids impossible, but a friendly acquisition at a 35 to 50 percent premium would force family decision-making. Most likely acquirer profiles: Almirall (Spanish specialty pharma peer), Recordati (Italian, similar profile), or a private-equity sponsor consolidating European specialty pharma assets.

Faes Farma is the kind of underfollowed Iberian family-pharma compounder that quietly pays you to wait. The bilastine royalty engine is genuinely high-quality cash flow with formulation-patent protection through 2030 to 2034, the dividend has 78 years of continuity, the beta is 0.34, and the family-ownership alignment keeps capital allocation conservative. Spanish broker consensus 5.20 EUR matches my sum-of-parts work, and the embedded Ingaso animal-nutrition asset is meaningfully undervalued at consolidated multiples.

I would size this as a 1.5 to 2.5 percent portfolio position with a 36-month horizon and a 3.60 EUR stop-loss (below the 52-week low). Upside scenarios cluster at 5.30 to 5.95 EUR; downside at 3.50 to 3.80. Risk-reward is roughly 1.5-to-1 favorable — not a multi-bagger, but a reliable cash-generating sleeve for the defensive healthcare portion of a portfolio. Best paired with higher-volatility healthcare exposure (Sarepta, Vaxart-style biotech) to balance overall portfolio beta.